Arixtra Abdominal Surgery, Acutely Ill Prophylaxis Filings Set For Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo and Organon will kick off their planned label expansion program for the anticoagulant Arixtra with a submission for treatment of venous thromboembolism in the third quarter and subsequent filings for prophylactic use in major abdominal surgery and acutely ill medical patients.